Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease

0 seconds of 0 secondsVolume 90%

00:00

Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease

AACR Annual Meeting 2022

Jia Luo, MD, of Dana-Farber Cancer Institute, discusses the emerging class of cancer therapies for allele-specific KRAS inhibitors and the importance of their distinct clinical, genomic, and immunologic features. Because KRAS G12D–mutated non–small cell lung cancer is associated with worse responses to immunotherapy, Dr. Luo believes drug development will need to take these differences into account (Abstract 4117).

Nicolas Girard, MD, PhD, on NSCLC: New Data on Event-Free Survival With Nivolumab Plus Platinum-Doublet Chemotherapy

Nicolas Girard, MD, PhD, of the Institut Curie, discusses findings from the phase III CheckMate 816 trial, which is the first study with an immunotherapy-based combination to demonstrate improved event-free survival and pathologic complete response in the neoadjuvant setting for patients with resectable stage IB to IIIA non–small cell lung cancer. The results may benefit the 30% to 55% of patients whose cancer recurs after surgery (Abstract CT012).

Gynecologic Cancers

The ASCO Post Staff

Benoit You, MD, PhD, on Endometrial Cancer: New Data on Combining Olaparib, Cyclophosphamide, and Metformin

Benoit You, MD, PhD, of the Lyon University Hospital (France), discusses phase I/II safety and efficacy results from the ENDOLA trial that combined olaparib with metronomic cyclophosphamide and metformin in patients with advanced pretreated endometrial cancer. At 10 weeks, the non–disease progression rate was 61.5%, reaching the primary endpoint of the study. Median progression-free survival was 5.1 months. Research on biomarkers of efficacy is ongoing (Abstract CT005).

Issues in Oncology

Genomics/Genetics

The ASCO Post Staff

Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research

Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, discusses the battle against treatment resistance and how to overcome it, as well as the power of observational clinical data in precision oncology, derived largely from his experience with Project GENIE, and the role of genetic ancestry (Abstract PL02).

Gastroesophageal Cancer

The ASCO Post Staff

Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy

Zev Wainberg, MD, of the University of California, Los Angeles Medical Center, discusses preliminary data on the safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with budigalimab and FOLFOX for the first-line treatment of locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. The study suggests the regimen may prove to be of benefit as a first-line treatment, regardless of combined positive score status (Abstract CT015).

Gastroesophageal Cancer

Gastrointestinal Cancer

Immunotherapy

The ASCO Post Staff

Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin

Gulam A. Manji, MD, PhD, of Columbia University Medical Center, discusses phase II results on perioperative combination chemotherapy and pembrolizumab in patients with resectable gastric cancer. The combination appeared to result in many complete pathologic responses (Abstract CT009).

Apr

Today In Oncology

Jia Luo, MD, on NSCLC: Clinicopathologic and Molecular Characterization of KRAS G12D–Mutated Disease

Related Videos

Nicolas Girard, MD, PhD, on NSCLC: New Data on Event-Free Survival With Nivolumab Plus Platinum-Doublet Chemotherapy

Benoit You, MD, PhD, on Endometrial Cancer: New Data on Combining Olaparib, Cyclophosphamide, and Metformin

Charles L. Sawyers, MD, on Transforming Patient Outcomes: The Future of Cancer Research

Zev Wainberg, MD, on Gastroesophageal Junction Adenocarcinoma: Early Results With Anti-CD39 Antibody Plus Chemoimmunotherapy

Gulam A. Manji, MD, PhD, on Gastric and Gastroesophageal Junction Adenocarcinomas: New Data on Pembrolizumab Plus Capecitabine and Oxaliplatin

Hypofractionation vs Conventional Fractionation in Patients With Breast Cancer Planning Breast Reconstruction

Rates of Breast, CRC Screenings Almost Four Times Higher Than Lung Cancer Screenings

Comparing Biopsy Techniques for Prostate Cancer Detection

Characteristics of Nasopharyngeal Carcinoma in the United States

Grocery Store Choice Could Impact Obesity Related Cancer Mortality